The faculty and researchers of the Myeloma Institute will present their research and clinical updates throughout the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta December 9-12.
The annual ASH meeting is considered by many to be the most comprehensive hematology event, with hematologists attending from across the globe to hear the latest advances in research and clinical practice. Other highlights of the conference include award presentations to former Vice President Joe Biden, as well as journalist and author Tom Brokaw, in recognition of their advocacy for research and hematology.
For a full schedule of oral and poster presentations where Myeloma Institute physicians and scientists are the speakers, moderator, or co-author, download the complete listing. Be sure to follow us on Twitter and Facebook for the latest news, videos, and events!
- Daratumamab in High Risk Relapse/Refractory Myeloma Patients; Effect of 1q21 Duplication and GEP70 Status
- Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma
- MAFA Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors
- Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots Within the Non-Coding Regions
- Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse
- MAF and NF-κB Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma
- Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients who Subsequently Relapse
- Nivolumab for Treatment of Advanced Refractory High-Risk Multiple Myeloma
- Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression